INS and Hyperglycemia: A post hoc analysis of patients enrolled in the C2305 trial showed that mean HbA1c levels after 12 months of treatment with pasireotide LAR were 6.6, 6.7 and 7.2 % in patients whose hyperglycemia was managed with metformin alone, metformin plus other oral antidiabetic medications, and insulin with or without other oral antidiabetic, respectively [27].